Teva reiterates interest in Mylan; Caforio in as BMS chief; China to nix price caps;

@FiercePharma: India eases path for small companies to bid in medical product tenders. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: ICYMI: Novo putting $225M into new plant in Denmark for hemophilia treatments. Report | Follow @EricPFierce

@CarlyHFierce: Big new launches rocket cancer drug spending to $100B: IMS report. More | Follow @CarlyHFierce

> Teva ($TEVA) has filed an updated investor presentation reiterating its $82-per-share Mylan ($MYL) buyout proposal. Release

> Giovanni Caforio has assumed the post of CEO at Bristol-Myers Squibb ($BMY). Report

> China will remove price caps for most therapies from June 1, and giving the market a larger role in setting prices in the country. More

> The Supreme Court has brought Bristol-Myers Squibb's hopes of reviving patent protection for its Baraclude hep B treatment to an end, declining to hear its challenge to an appeals court ruling in favor of copycat drugmaker Teva. Report

> Teva has closed its $3.2 billion acquisition of Auspex Pharmaceuticals. Report

> Mallinckrodt ($MNK) said its profit leapt in its latest quarter, and it lifted its outlook for the year after recent pickup Ikaria helped boost sales. Report

Medical Device News

@FierceMedDev: Myriad Genetics stumbles as rivals flood BRCA market. FierceDiagnostics story | Follow @FierceMedDev

@EmilyWFierce: Scientists harness new technology for artificial knee implants. Report | Follow @EmilyWFierce

> Open-source software released to connect Apple ResearchKit to the cloud for use in clinical trials. News

> Researchers question safety of off-label device use in atrial fibrillation, call for 510(k) review process. Report

Biotech News

@FierceBiotech: ICYMI yesterday: Bayer fronting $155M for a promising anticoagulant from Isis Pharma. Report | Follow @FierceBiotech

@JohnCFierce: The drumbeat of bad news at $GSK should lead to a change of CEOs. Breaking up the co. will be the focus as well. More from Bloomberg | Follow @JohnCFierce

> Tobira pulls off a $40M Wall Street end-around with sights set on NASH. More

> Roche presses pause on PTC's SMA drug over a safety scare. Article

> Corbus who? A tiny biotech is shoved into the rink with a hulking Vertex. Story

> GlaxoSmithKline files for gene therapy OK as a case of the jitters sets in. Report

Pharma Manufacturing News

> Zoetis to whack 10 plants as part of cost-cutting scheme. News

> U.K. regulators find issues with Indian-owned API distributor Relonchem. More

> WuXi starts work in China on yet another cell-line manufacturing facility. Article

> Recro Pharma and Alkermes close deal on DEA-approved plant in Georgia. Story

> Novo building $225M plant for hemophilia treatments. Report

Pharma Asia News

> China's SAIC denies probe as reports proliferate on alleged devices crackdown. Article

> India eases path for small companies to bid in medical product tenders. Story

> China plans first-ever rules on animal testing in medical research by year end. More

> Otsuka device unit works with UniCare on urinary bladder products. Report

> Japan to adopt CDISC clinical data standards from October 2016. Item

Drug Delivery News

> NIH says viral vector for delivering gene therapy to treat blindness shows promise, Wall Street less sure. More

> UNC scientists bypass blood-brain barrier with exosomes to treat Parkinson's. Report

> Northwestern team puts spherical RNA in common skin moisturizer to speed up wound healing. Story

> Medicines Co. gets FDA approval of first patient-controlled patch for postoperative pain. Item

> Deerfield Management buys 8% stake in manufacturer of custom hydrogels and wound dressings. Article

And Finally... A drug derived from Caribbean reefs may treat psoriasis and multiple sclerosis. Story

Suggested Articles

Hecht recently sat down with Fierce Pharma to discuss how Ora supports their customers and site partners.

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.

BMS executives pointed to upcoming Opdivo data releases, as well as strong demand for other drugs in the portfolio, as reasons for optimism.